AZN
AstraZeneca PLC
NYSE: AZN · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$177.34
-0.79% today
Updated 2026-06-15
Market cap
$282.69B
P/E ratio
27.49
P/S ratio
4.68x
EPS (TTM)
$6.63
Dividend yield
1.79%
52W range
$135 – $211
Volume
2.0M
AstraZeneca PLC (AZN) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed AZN price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$177.34
Today
Analyst consensus
$224.49
+26.59% · 12M
2030 Base
$164.40
-7.30% future
NPV today
$127.33
@ 6% WACC
33 analysts:
12 Buy1 Hold1 Sell
Management guidance
AstraZeneca's CEO Pascal Soriot has not provided explicit 2026-2030 revenue targets in recent guidance. However, the company has guided toward 'strong growth' in oncology and specialty care, with recent Q1 2026 results showing $15.29B in quarterly revenue (+12.5% YoY). Management emphasizes a diversified pipeline across oncology, respiratory, cardiovascular/renal/metabolic (CVRM), and vaccines, with multiple late-stage catalysts expected through 2028-2030.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
AZN · AstraZeneca PLC · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$82.37
NPV today: $63.79
Base case (2030)
$164.40
NPV today: $127.33
Bull case (2030)
$410.47
NPV today: $317.90
WallStSmart.com
AZN financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $58.7B | $72.8B | $86.2B | $100.4B | $114.2B | $127.8B |
| Revenue growth | 8.6% | 24.0% | 18.4% | 16.5% | 13.8% | 12.0% |
| Net margin | — | 13.0% | 13.2% | 13.2% | 12.9% | 12.9% |
| EPS | $3.52 | $6.10 | $7.35 | $8.55 | $9.50 | $10.60 |
| Diluted shares | — | 1552M | 1553M | 1555M | 1556M | 1558M |
| Net debt | — | $20.40B | $16.19B | $11.29B | $5.71B | $-537.00M |
| P/S multiple | — | 2.0x | 2.0x | 2.0x | 2.0x | 2.0x |
| Implied price (base) | — | $80.68 | $100.56 | $121.88 | $143.07 | $164.40 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $127.8B | $127.8B | $127.8B |
| P/S multiple | 1.0x | 2.0x | 5.0x |
| Diluted shares | 1558M | 1558M | 1558M |
| Net debt | $-537.00M | $-537.00M | $-537.00M |
| Implied P/E † | 8x | 16x | 39x |
| 2030 Price | $82.37 | $164.40 | $410.47 |
| NPV @ 6% | $63.79 | $127.33 | $317.90 |
† Implied P/E: Multiples remain elevated across all three scenarios because AZN is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $164.40 base case
AZN catalysts and risks
Growth catalysts
+ FDA approval of Baxfendy (aldosterone synthase inhibitor) with $5B+ peak sales potential and expansion into chronic kidney disease
+ Positive Phase III VOLGA data for Imfinzi in muscle-invasive bladder cancer; potential label expansion in early-stage disease
+ Enhertu label expansions: 9 approved indications across HER2-positive breast cancer, HER2-low breast cancer, and gastric cancer; peak sales potential $5-7B
+ Tozorakimab (IL-4R antagonist) Phase III MIRANDA completion in COPD; potential $3-5B peak sales if approved
+ CVRM portfolio growth: Farxiga (SGLT2i) expansion, Tagrisso (EGFR inhibitor) patent extension in key markets, Baxfendy launch acceleration
+ Oncology innovation pipeline: multiple Phase III readouts 2026-2028 in solid tumors, hematologic malignancies
+ Vaccines portfolio strength: respiratory syncytial virus (RSV), influenza, and other immunization opportunities
Key risks
- Patent expirations: Tagrisso (EGFR inhibitor) faces biosimilar/generic competition starting ~2028-2030 in key markets; potential $2-3B revenue headwind
- Pricing pressure: US regulatory environment (drug price negotiation under Biden-era reforms, Trump administration tariff risk) could compress margins or cap revenue growth
- Clinical/regulatory setbacks: FDA panel voted against camizestrant (oral breast cancer) in May 2026; future pipeline failures could derail growth
- China market dynamics: slowing growth in Chinese oncology market, pricing pressure on Tagrisso and Imfinzi in China
- Competitive intensity: Merck (Keytruda), Bristol-Myers Squibb, Pfizer, Novo Nordisk (GLP-1 expansion) accelerating in oncology, metabolic disease, and CVRM
- Currency headwinds: ~30-35% of revenues from non-USD markets; GBP/EUR weakness could offset volume growth
Methodology · AstraZeneca PLC 2030 stock forecast model
AstraZeneca PLC 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 33 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (0% cumulative for AZN by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-537.00M by 2030) |
| 3. Time value | NPV calculated using 6% WACC (CAPM: beta 0.223) |
| 4. Multiple framework | P/S compresses with scale: bear 1.0x / base 2.0x / bull 5.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 21, 2026.
AZN price target FAQ
What is the AZN price target for 2030?
WallStSmart's AstraZeneca PLC 2030 base case is $164.40 per share, with a bull case of $410.47 and bear case of $82.37. The NPV of the base case discounted to today at 6% WACC is $127.33.
How is the AstraZeneca PLC 2030 stock forecast calculated?
The AZN 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the AZN price target account for dilution?
AstraZeneca PLC is projected to grow diluted share count from 1551M to 1558M by 2030 (a 0% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 0%.
What is the analyst consensus on AZN stock?
33 analysts cover AZN with an average 12-month price target of $224.49. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.